Vaxcyte Announces Closing of $862.5 Million Public Offering

SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...

Related Keywords

Charlotte ,North Carolina ,United States ,New York ,Boston ,Massachusetts ,Jennifer Zibuda ,Janet Graesser ,Groupa Strep ,Vaxcyte Inc ,Sutro Biopharma Inc ,Equity Syndicate Department ,Syndicate Department ,Nasdaq ,Needham Company ,Evercore Group ,Corporate Communications ,Leerink Partners ,Prospectus Department ,Exchange Commission ,Guggenheim Securities ,Bofa Securities ,Tryon Street ,Equity Capital Markets ,Sutro Biopharma ,Vice President ,Senior Director ,Nasdaq Pcvx ,Maxcyte ,Nc ,Biotech ,Vaccines ,Healthcare ,